%PDF-1.4
%
51 0 obj
<>
endobj
48 0 obj
<>
endobj
143 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2003-09-08T17:55:16Z
2024-03-28T13:57:32-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-28T13:57:32-07:00
application/pdf
Heather
2002-887.oct
uuid:c0de1edd-1dd1-11b2-0a00-2f09277d8900
uuid:c0de1ee0-1dd1-11b2-0a00-d30000000000
endstream
endobj
37 0 obj
<>
endobj
38 0 obj
<>
endobj
52 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 23 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 25 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 27 0 R/Type/Page>>
endobj
12 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 29 0 R/Type/Page>>
endobj
20 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 31 0 R/Type/Page>>
endobj
164 0 obj
[169 0 R]
endobj
165 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.00011 Tc 0.0914 Tw 10 0 0 10 54 713.1616 Tm
[(for the epidemiological characteristics of our patients. )18 (The)]TJ
0.0199 Tc 0.37801 Tw 0 -1.2 TD
(high prevalence of anti DNA-topoisomerase positive)Tj
-0.00011 Tc 0.138 Tw T*
(patients is a well established feature of our series)Tj
0 Tc 0 Tw 6.5 0 0 6.5 261.0566 692.4616 Tm
(14,31)Tj
-0.00011 Tc 10 0 0 10 279.5616 689.1616 Tm
(and)Tj
0.0094 Tw -22.5562 -1.2 Td
(may relate to unestablished ethnic or environmental factors.)Tj
-0.0101 Tc 0.1579 Tw 1.2 -1.2 Td
[(Our preliminary study shows that an increased )37 (YKL-40)]TJ
0.2524 Tw -1.2 -1.2 Td
(serum concentration occurs in many SSc patients, and is)Tj
0.1076 Tw T*
[(related to )18 (T)-330 (cell activation, as shown by IL-2R)]TJ
/T1_1 1 Tf
0 Tc 0 Tw 18.9877 0 Td
(\002)Tj
/T1_0 1 Tf
-0.0101 Tc 0.1077 Tw 0.9685 0 Td
(levels and)Tj
0.1825 Tw -19.9562 -1.2 Td
[(joint involvement. )18 (This could indicate that )37 (YKL-40 serum)]TJ
0.0056 Tw T*
[(changes reflect cartilage and/or synovial fibroblast activity)65 (. )55 (A)]TJ
0.05389 Tw T*
[(longitudinal study is needed to address the value of )37 (YKL-40)]TJ
0.03909 Tw T*
(as a serological marker of joint disease in systemic sclerosis,)Tj
0.00079 Tw T*
(and its use in monitoring clinical changes and drug influence.)Tj
/T1_2 1 Tf
-0.00011 Tc 0 Tw 0 -2.4 TD
(ACKNOWLEDGMENT)Tj
/T1_0 1 Tf
-0.0072 Tw 8 0 0 8 54 547.1616 Tm
[(W)80 (e are grateful to Dr)55 (. Salvatore )55 (Abbadessa for skillful technical assistance. )]TJ
/T1_2 1 Tf
0 Tw 10 0 0 10 54 523.1616 Tm
(REFERENCES)Tj
/T1_0 1 Tf
0.02499 Tw 8 0 0 8 61 513.1616 Tm
[(1.)-875 (Clements PJ, Furst DE. Systemic Sclerosis. Baltimore: )18 (W)40 (illiam and)]TJ
1.675 -1.25 Td
[(W)40 (ilkins; 1996.)]TJ
-1.675 -1.25 Td
[(2.)-875 (Blocka KLN, Bassett L)74 (W)92 (, Furst DE, Clements PJ, Paulus HE. )18 (The)]TJ
1.675 -1.25 Td
(arthropathy of advanced progressive systemic sclerosis. )Tj
0 -1.25 TD
[(A)-220 (radiographic survey)65 (. )55 (Arthritis Rheum 1981;24:874-84.)]TJ
-1.675 -1.25 Td
[(3.)-875 (Hakala BE, )18 (White C, Recklies )55 (AD. Human cartilage gp-39, a major)]TJ
1.675 -1.25 Td
(secretory product of articular chondrocytes and synovial cells, is a)Tj
T*
[(mammalian member of a chitinase protein family)65 (. J Biol Chem)]TJ
0 Tc 0 Tw T*
(1993;208:25803-10.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(4.)-875 (De Ceuninck F)80 (, Gaufillier S, Bonnaud )55 (A, Sabatini M, Lesur C,)]TJ
1.675 -1.25 Td
[(Pastoureau P)111 (. )37 (YKL-40 \(cartilage gp-39\) induces proliferative events)]TJ
T*
(in cultured chondrocytes and synoviocytes and increases)Tj
T*
(glycosaminoglycan synthesis in chondrocytes. Biochem Biophys)Tj
0 Tc T*
(Res Commun 2001;285:926-31.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(5.)-875 (Johansen JS, Olee )18 (T)74 (, Price P)92 (A, Hashimoto S, Ochs RL, Lotz M.)]TJ
1.675 -1.25 Td
[(Regulation of )37 (YKL-40 production by human articular )]TJ
T*
[(chondrocytes. )55 (Arthritis Rheum 2001;44:826-37.)]TJ
-1.675 -1.25 Td
[(6.)-875 (Recklies )55 (AD, )18 (White C, Ling H. )18 (The chitinase 3-like protein human)]TJ
1.675 -1.25 Td
(cartilage glycoprotein 39 \(HC gp39\) stimulates proliferation of)Tj
T*
(human connective-tissue cells and activates both extracellular)Tj
T*
(signal-regulated kinase- and protein kinase B-mediated signaling)Tj
T*
[(pathways. Biochem J 2002;365:1)37 (19-26.)]TJ
-1.675 -1.25 Td
[(7.)-875 (T)35 (ran )55 (A, Benzaken S, Saint-Paul MC, et al. Chondrex \(YKL-40\), a)]TJ
1.675 -1.25 Td
(potential new serum fibrosis marker in patients with alcoholic liver)Tj
T*
(disease. Eur J Gastroenterol Hepatol 2000;12:989-93.)Tj
-1.675 -1.25 Td
[(8.)-875 (Johansen JS, Christof)18 (fersen P)111 (, Moller S, et al. Serum )37 (YKL-40 is)]TJ
1.675 -1.25 Td
(increased in patients with hepatic fibrosis. J Hepatol )Tj
0 Tc 0 Tw T*
[(2000;32:91)37 (1-20. )]TJ
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(9.)-875 (Harvey S, )18 (W)80 (eisman M, O\325Dell J, et al. Chondrex: )55 (A)-220 (new marker of)]TJ
1.675 -1.25 Td
(joint disease. Clin Chem 1998;3:509-16. )Tj
-2.175 -1.25 Td
[(10.)-875 (Johansen JS, Jensen HS, Price P)92 (A. )55 (A)-220 (new biochemical marker for)]TJ
2.175 -1.25 Td
[(joint injury)65 (. )55 (Analysis of )37 (YKL-40 in serum and synovial fluid. Br )]TJ
T*
(J Rheumatol 1993;32:949-55. )Tj
-2.1381 -1.25 Td
[(1)37 (1.)-875 (Matsumoto )18 (T)74 (, )18 (T)70 (surumoto )18 (T)74 (. Serum )37 (YKL-40 levels in rheumatoid)]TJ
2.1381 -1.25 Td
(arthritis: Correlations between clinical and laboratory parameters.)Tj
T*
(Clin Exp Rheumatol 2001;19:655-60.)Tj
-2.175 -1.25 Td
[(12.)-875 (Garnero P)111 (, Piperno M, Gineyts E, Christgau S, Delmas PD, Mignon)]TJ
2.175 -1.25 Td
(E. Cross sectional evaluation of biochemical markers of bone, )Tj
T*
(cartilage, and synovial tissue metabolism in patients with knee)Tj
T*
[(osteoarthritis: relations with disease activity and joint damage. )55 (Ann)]TJ
0 Tc T*
(Rheum Dis 2001;60:619-26. )Tj
-0.00011 Tc -2.175 -1.25 Td
[(13.)-875 (Subcommittee for Scleroderma Criteria of the )55 (American)]TJ
2.175 -1.25 Td
[(Rheumatism )55 (Association Diagnostic and )18 (Therapeutic Criteria)]TJ
T*
(Committee. Preliminary criteria for the classification of systemic)Tj
T*
[(sclerosis \(scleroderma\). )55 (Arthritis Rheum 1980;23:581-90. )]TJ
30.825 80.171 Td
[(14.)-875 (Giordano M, )18 (V)111 (alentini G, Migliaresi S, Picillo U, )18 (V)111 (atti M. Dif)18 (ferent)]TJ
2.175 -1.25 Td
[(antibody patterns and dif)18 (ferent prognoses in patients with )]TJ
T*
(scleroderma with various extent of skin sclerosis. J Rheumatol)Tj
0 Tc 0 Tw T*
[(1986;13:91)37 (1-6.)]TJ
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(15.)-875 (Clements PJ, Lachenbruch M, Seibold JR, et al. Inter and intra)]TJ
2.175 -1.25 Td
(observer variability of total skin thickness score \(modified-Rodnan\))Tj
T*
(in systemic sclerosis. J Rheumatol 1995;22:1281-5.)Tj
-2.175 -1.25 Td
[(16.)-875 (Medsger )18 (T)80 (A)-220 (Jr)40 (, Silman )55 (AJ, Steen )18 (VD, et al. )55 (A)-220 (disease severity scale)]TJ
2.175 -1.25 Td
(for systemic sclerosis: development and testing. J Rheumatol)Tj
0 Tc 0 Tw T*
(1999;26:2159-67.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(17.)-875 (Herrick )55 (AL, Illingworth K, Blann )55 (A, Hay CRM, Hollis S, Jayson)]TJ
2.175 -1.25 Td
[(MIV)129 (. )18 (V)129 (on )18 (W)40 (illebrand factor)40 (, thrombomodulin, thromboxane, beta)]TJ
T*
[(thromboglobulin and markers of fibrinolysis in primary Raynaud\325)55 (s)]TJ
T*
[(phenomenon and systemic sclerosis. )55 (Ann Rheum Dis )]TJ
0 Tc 0 Tw T*
(1996;55:122-7.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(18.)-875 (Black CM, McWhirter )55 (A, Harrison NK, Kirm JME, Laurent CJ.)]TJ
2.175 -1.25 Td
(Serum type III procollagen peptide concentrations in systemic )Tj
T*
[(sclerosis and Raynaud\325)55 (s phenomenon: relationship to disease)]TJ
T*
(activity and duration. Br J Rheumatol 1989;28:98-103.)Tj
-2.175 -1.25 Td
[(19.)-875 (Steen )18 (VD, Engel EE, Charley MR, Medsger )18 (T)80 (A. Soluble serum)]TJ
2.175 -1.25 Td
(interleukin-2 receptors in patients with systemic sclerosis. )Tj
T*
(J Rheumatol 1996;23:46-9.)Tj
-2.175 -1.25 Td
[(20.)-875 (La Montagna G, Baruf)18 (fo )55 (A, )18 (T)35 (irri R, Buono G, )18 (V)111 (alentini G. Foot)]TJ
2.175 -1.25 Td
[(involvement in systemic sclerosis: )55 (A)-220 (longitudinal study of 100)]TJ
T*
[(patients. Semin )55 (Arthritis Rheum 2002;31:248-55.)]TJ
-2.175 -1.25 Td
[(21.)-875 (Rodnan GP)111 (. )18 (The nature of joint involvement in progressive)]TJ
2.175 -1.25 Td
[(systemic sclerosis \(dif)18 (fuse scleroderma\). Clinical study and )]TJ
T*
[(pathologic examination of synovium in 29 patients. )55 (Ann Intern Med)]TJ
0 Tc 0 Tw T*
(1962;56:422-38.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(22.)-875 (V)129 (olck B, Oster)18 (gaard K, Johansen JS, Garbarsch C, Price P)92 (A. )18 (The)]TJ
2.175 -1.25 Td
[(distribution of )37 (YKL-40 in osteoarthritic and normal human articular)]TJ
T*
(cartilage. Scand J Rheumatol 1999;28:171-9.)Tj
-2.175 -1.25 Td
[(23.)-875 (V)129 (os K, Steenbakkers P)111 (, Miltenbur)18 (g )55 (AMM, et al. Raised human)]TJ
2.175 -1.25 Td
(cartilage glycoprotein-39 plasma levels in patients with rheumatoid)Tj
T*
[(arthritis and other inflammatory conditions. )55 (Ann Rheum Dis)]TJ
0 Tc 0 Tw T*
(2000;59:544-48.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(24.)-875 (Conrozier )18 (Th, Carlier MC, Mathieu P)111 (, et al. Serum levels of )]TJ
2.175 -1.25 Td
(YKL-40 and C reactive protein in patients with hip osteoarthritis)Tj
T*
[(and healthy subjects: a cross sectional study)65 (. )55 (Ann Rheum Dis)]TJ
0 Tc 0 Tw T*
(2000;59:828-31.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(25.)-875 (Johansen JS, Hvorlis J, Hansen M, Backer )18 (V)129 (, Lorenzen I, Price P)92 (A.)]TJ
2.175 -1.25 Td
[(Serum )37 (YKL-40 levels in healthy children and adults, comparison)]TJ
T*
[(with serum and synovial fluid levels of )37 (YKL-40 in patients with)]TJ
T*
(osteoarthritis or trauma of the knee joint. Br J Rheumatol)Tj
0 Tc 0 Tw T*
(1996;35:553-9.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(26.)-875 (Cintin C, Johansen JS, Christiansen IJ, Price P)92 (A, Sorensen S,)]TJ
2.175 -1.25 Td
[(Nielsen HJ. Serum )37 (YKL-40 and colorectal cancer)55 (. Br J Cancer)]TJ
0 Tc 0 Tw T*
(1999;79:1494-9.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(27.)-875 (V)111 (erheijden GFM, Rijnders )55 (A)80 (WM, Bos E, et al. Human cartilage)]TJ
2.175 -1.25 Td
(glycoprotein-39 as a candidate autoantigen in rheumatoid arthritis.)Tj
T*
[(Arthritis Rheum 1997;40:1)37 (1)37 (15-25.)]TJ
-2.175 -1.25 Td
[(28.)-875 (Peltomaa R, Paimela L, Harvey S, Helve )18 (T)74 (, Leirisalo-Repo M.)]TJ
2.175 -1.25 Td
[(Increased level of )37 (YKL-40 in sera from patients with early )]TJ
T*
[(rheumatoid arthritis: a new marker for disease activity)65 (. Rheumatol)]TJ
T*
(Int 2001;20:192-6.)Tj
-2.175 -1.25 Td
[(29.)-875 (Johansen JS, Stoltenber)18 (g M, Hansen M, et al. Serum )37 (YKL-40)]TJ
2.175 -1.25 Td
(concentrations in patients with rheumatoid arthritis: Relation to)Tj
0 Tc T*
[(disease activity)65 (. Rheumatology 1999;38:618-26.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(30.)-875 (Harvey S, )18 (Whaley J, Eberhardt K. )18 (The relationship between serum)]TJ
2.175 -1.25 Td
[(levels of )37 (YKL-40 and disease progression in patients with early)]TJ
T*
(rheumatoid arthritis. Scand J Rheumatol 2000;29:391-3.)Tj
-2.175 -1.25 Td
[(31.)-875 (Picillo U, Migliaresi S, )18 (V)111 (atti M, Marcialis MR, Ferruzzi )55 (AM, )18 (T)35 (irri)]TJ
2.175 -1.25 Td
[(G. Demographic dif)18 (ferences in the frequencies of )]TJ
T*
[(scleroderma-related autoantibodies. )55 (Arthritis Rheum )]TJ
0 Tc 0 Tw T*
(1993;36:1332-4.)Tj
ET
0 0 0 0 k
408 770 150 -25 re
f*
0 0 0 1 K
54 54 m
558 54 l
S
BT
0 0 0 1 k
/T1_3 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 54.5 35.9844 Tm
(La Montagna, et al: YKL-40 in SSc)Tj
0 Tc 0 Tw 60.9375 -0.0313 Td
(2151)Tj
ET
0 0 0 0 k
/GS0 gs
109.22 59.09 396.48 -10.84 re
f*
0.5 w
109.22 59.09 396.48 -10.84 re
S
/GS1 gs
408 770 150 -25 re
f*
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
ET
/GS2 gs
BT
/T1_4 8 Tf
117.48 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2003. All rights reserved.)Tj
ET
Q
BT
0 g
/GS3 gs
/T1_5 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS3 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS3 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
31 0 obj
<>stream
8;Z\6!H,gu%*SZ8R."iiM=%Z8C!&8,)`r%$M)pLRR(E=$nM2o0YPn'>".%Vkp`AcT
0:ORaf0&hO1Ha`A_A^3MHet?WLCa/-)<8I6.EVYY)/WD]43W$.o!NOi44'%*,r&@&
VB&ADhE$'I,Ns'9nt?"_p"!BaV9!>m0X%!M`D[QKB^n*?KXN@a/lQk]QNcE2#8H_3
b=2014"tG=Y-&N-NL>#hYW^!H;:>iTRX4Mg6/i.&@Bqik[3>0JArWQQqAs_1YoKZ1
V;#;NQ18S'lW:O6+#I1I"A)2f#$>)D2j<=?45E2G*!'n$jpAI-m65q1U2FXTKPF2s
oW+0dqB>`!qGiGuZF%EJRU1ln_JlI`TQG@P8Wju',3V.+cB4'C`g3Z+hS`#S[$jNS
1q-[>,!(+X4E+4>Y"oqlo1[n-p)+0(->u\HqX!j-@g>sK*mTVfa([7<0DF?fJ^MW'2Zfi\X$6.<*?E+%a*h6MAA<^Gn%9jH=!SbK/^789^V\C+g=^ER&^
3n,Y4n'"u#*Yn54T!Nn<*pR:bd(HV8r5a6p6pW!g1:2_(CunP45>%48((aj2j1irD;5?
141dPX[EM:b&t_a>R+!L3B%rI-u;2S0n9!_U?^E'#e.q[[&'bq'h0EAdda#NcGIjX
!f>mgUu-nrMH?
endstream
endobj
35 0 obj
[/Indexed/DeviceRGB 255 34 0 R]
endobj
34 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
63 0 obj
<>
endobj
78 0 obj
<>
endobj
70 0 obj
<>
endobj
60 0 obj
<>
endobj
98 0 obj
<>
endobj
149 0 obj
<>
endobj
57 0 obj
<>
endobj
93 0 obj
<>stream
HUkPS>'I6<<#>UJaAD <